BOSTON, Nov. 2, 2018 /PRNewswire/ -- According to an announcement today by Life Biosciences Inc., Dr. Bill Avery and Dr. Michel Wathier have been appointed vice presidents. Dr. Avery is the vice president for nonclinical safety, providing preclinical development and translational program management, operation, and regulatory expertise. Dr. Michel Wathier is vice president of chemistry manufacturing and control (CMC), with specific expertise across devices, small and large molecules, and combination products. Their technical acumen supports Life Biosciences and its six Daughter companies as they pursue independent and collaborative research and development into the eight pathways of age-related decline (ARD).
"Bill and Michel bring to our company a remarkable depth of scientific, regulatory and business experience," said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. "We are excited for them to work at both the enterprise level and with our Daughter companies to develop drugs, therapies and treatments designed to reduce and reverse age-related decline."
Dr. Avery brings to Life Biosciences 18 years of developing drugs in successful biotechnology companies. During his career, he has led non-clinical development for 20 investigational new drug (IND) filings and 3 Biologics License Applications (BLA) registrations. He received his undergraduate degree from the University of Massachusetts, Amherst, in Veterinary and Animal Sciences, his JD and MBA from Suffolk University and his PhD in Health Sciences from Trident University. He is a Diplomat of the American Board of Toxicology.
Dr. Wathier's career encompasses more than 20 years of leading the formulation development and manufacture of drugs and biologics. His expertise is in leading complex drug substance and drug product manufacturing processes through drug approval. He has worked in regulatory environments in both the United States and internationally. He has led 15 compounds through successful IND filings. He received his PhD in Chemistry from the University of Avignon, France and completed his postdoctoral fellowship at Duke University in the department of chemistry.
Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of LifeLab, its 24,000 square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities; and an emerging AI platform being developed by the company's Lua subsidiary. Life Biosciences seeks to increase healthspans for everyone, including companion animals.
For more information on Life Biosciences, please visit www.lifebiosciences.com.
Press Contact: [email protected] [email protected]
Advertisement
"Bill and Michel bring to our company a remarkable depth of scientific, regulatory and business experience," said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. "We are excited for them to work at both the enterprise level and with our Daughter companies to develop drugs, therapies and treatments designed to reduce and reverse age-related decline."
Advertisement
Dr. Avery brings to Life Biosciences 18 years of developing drugs in successful biotechnology companies. During his career, he has led non-clinical development for 20 investigational new drug (IND) filings and 3 Biologics License Applications (BLA) registrations. He received his undergraduate degree from the University of Massachusetts, Amherst, in Veterinary and Animal Sciences, his JD and MBA from Suffolk University and his PhD in Health Sciences from Trident University. He is a Diplomat of the American Board of Toxicology.
Dr. Wathier's career encompasses more than 20 years of leading the formulation development and manufacture of drugs and biologics. His expertise is in leading complex drug substance and drug product manufacturing processes through drug approval. He has worked in regulatory environments in both the United States and internationally. He has led 15 compounds through successful IND filings. He received his PhD in Chemistry from the University of Avignon, France and completed his postdoctoral fellowship at Duke University in the department of chemistry.
Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of LifeLab, its 24,000 square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities; and an emerging AI platform being developed by the company's Lua subsidiary. Life Biosciences seeks to increase healthspans for everyone, including companion animals.
For more information on Life Biosciences, please visit www.lifebiosciences.com.
Press Contact: [email protected] [email protected]
View original content:http://www.prnewswire.com/news-releases/two-respected-scientists-join-the-life-biosciences-roster-300743051.html
SOURCE Life Biosciences
